SyntheticMR AB (“SyntheticMR” or the “Company”) has today, the 2nd of January 2025, acquired all shares in Finnish Combinostics Oy (“Combinostics”).The purchase price amounts to a total of EUR 4.3 million (corresponding to approximately SEK 49.6 million[1] ), of which approximately EUR 3.93 million (corresponding to approximately SEK 45.3 million) is paid in cash, and the remaining part of approximately EUR 0.37 million (corresponding to approximately SEK 4.3 million) through a promissory note set off against convertibles. The conversion price for the convertibles will be SEK 12 and the convertibles will be automatically converted into shares after the publication of the Company’s quarterly report for the third quarter of 2027, however no later than 30 November 2027.
[1] Calculated on the basis of a EUR/SEK exchange rate of 11.5401.
SynthethicMR AB has now acquired all shares and securities in the Finnish company Combinostics. Combinostics is a leading player in medical technology and software solutions, focusing on cloud-based and AI-driven platforms that offer advanced diagnostic tools and clinical decision support for healthcare providers. The acquisition is a strategic step in SyntheticMR’s growth plan and is designed to strengthen the Company’s market position and future competitiveness by combining the technology and expertise of the two companies.
The total purchase price for the acquisition amounts to EUR 4.3 million (corresponding to approximately SEK 49.6 million), of which approximately EUR 3.93 million (corresponding to approximately SEK 45.3 million) has been paid in cash at closing, of which EUR 0.86 million (corresponding to approximately SEK 9.9 million) will be placed in escrow for one year from closing, while the remaining amount of approximately EUR 0.37 million (corresponding to approximately SEK 4.3 million) will be settled through a promissory note. The promissory note has been offset against newly issued convertibles in SyntheticMR. The convertibles are issued at a conversion price of SEK 12 per share and will be automatically converted into shares in SyntheticMR after the publication of the Company’s quarterly report for the third quarter of 2027, however no later than 30 November 2027. Upon full conversion of issued convertibles, the number of shares in the Company will increase by 356,907 shares and the share capital by SEK 7,923.3354, which means a dilution of approximately 0.85 percent.
Advisors
Foyen Advokatfirma is acting as legal advisor to SyntheticMR in connection with the acquisition.
For further information, please contact:
Johanna Norén, CFO and Head of Investor Relations
Phone: + 46 70 619 21 00
E-mail: johanna.noren@syntheticmr.com
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI MSK is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.
